• Explore /
  • Poster
  • / Real-world outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) and tumors harboring androgen receptor (<em>AR</em>) ligand-binding domain (LBD) mutations.

Real-world outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) and tumors harboring androgen receptor (AR) ligand-binding domain (LBD) mutations.

Abstract Poster

Authors

null

Tyler F. Stewart

University of California, San Diego Health, La Jolla, CA

Tyler F. Stewart , David Chandiwana , Ashley Doyle , Nana Boame , Jayati Saha , Nicole Zhang , Darrin Benjumea , Andrew Rava , Janaki Parameswaran , Michelle L. Edwards , Joshua Michael Lang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Quality of Care/Quality Improvement and Real-World Evidence

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 77)

DOI

10.1200/JCO.2024.42.4_suppl.77

Abstract #

77

Poster Bd #

C12

Abstract Disclosures

Similar Posters

First Author: Pedro C. Barata

Poster

2023 ASCO Genitourinary Cancers Symposium

A real-world registry of patients with metastatic castration-resistant prostate cancer (mCRPC): REMPRO study.

A real-world registry of patients with metastatic castration-resistant prostate cancer (mCRPC): REMPRO study.

First Author: Francisco Gonzalez

First Author: Jeetvan Patel

First Author: Neal D. Shore